Online inquiry

IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8562MR)

This product GTTS-WQ8562MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers(CRC), Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8562MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3259MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ13824MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ10461MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ12417MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ7293MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ9846MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ5631MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP870
GTTS-WQ13577MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA QAX-576
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW